The way I see it. If the results look on par with the phase II for rGBM, I see the company either as a. a buyout candidate or b. a major partnership, exploiting the possible implications of combination therapy with various agents. Either way, it's looking good. From reading the Inspire thread, I'm convinced the feverish issue is a strong marker for VB-111 response.
News 
Market Data 
Discover 
